Influenza Viral Challenge Study of CC-42344 in Healthy Participants
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Participants in this study will be given either CC-42344 (one of two dose levels) or placebo
orally for 5 days after receiving an influenza (flu) challenge virus. Participants will not
know whether they are getting placebo or CC-42344. The amount of virus in nasal samples will
be measured over time. Side effects and pharmacokinetics (the amount of CC-42344 in blood)
will also be measured.